Lingohr Asset Management GmbH Has $5.34 Million Stock Position in Medtronic PLC $MDT

Lingohr Asset Management GmbH increased its holdings in shares of Medtronic PLC (NYSE:MDT) by 456.6% in the third quarter, according to its most recent disclosure with the SEC. The firm owned 56,075 shares of the medical technology company’s stock after purchasing an additional 46,000 shares during the period. Lingohr Asset Management GmbH’s holdings in Medtronic were worth $5,341,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. AXQ Capital LP increased its position in Medtronic by 25.6% during the 2nd quarter. AXQ Capital LP now owns 9,890 shares of the medical technology company’s stock worth $862,000 after buying an additional 2,013 shares during the period. Merit Financial Group LLC increased its position in Medtronic by 37.5% during the second quarter. Merit Financial Group LLC now owns 57,035 shares of the medical technology company’s stock worth $4,972,000 after acquiring an additional 15,561 shares during the period. Verdence Capital Advisors LLC raised its stake in Medtronic by 22.0% in the 2nd quarter. Verdence Capital Advisors LLC now owns 29,396 shares of the medical technology company’s stock worth $2,562,000 after purchasing an additional 5,296 shares in the last quarter. Sector Gamma AS boosted its holdings in Medtronic by 35.5% in the 3rd quarter. Sector Gamma AS now owns 303,441 shares of the medical technology company’s stock valued at $28,900,000 after purchasing an additional 79,441 shares during the period. Finally, World Investment Advisors grew its position in shares of Medtronic by 1.9% during the 2nd quarter. World Investment Advisors now owns 156,107 shares of the medical technology company’s stock worth $13,608,000 after purchasing an additional 2,868 shares in the last quarter. Institutional investors own 82.06% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the stock. UBS Group lifted their price target on shares of Medtronic from $95.00 to $102.00 and gave the company a “neutral” rating in a research report on Wednesday, November 19th. Daiwa Capital Markets raised their price objective on Medtronic from $104.00 to $117.00 and gave the stock a “buy” rating in a research note on Tuesday, November 25th. Wells Fargo & Company assumed coverage on Medtronic in a research report on Friday. They set an “overweight” rating and a $114.00 target price for the company. William Blair raised Medtronic from a “market perform” rating to an “outperform” rating in a report on Tuesday, January 6th. Finally, Leerink Partners set a $120.00 price target on Medtronic and gave the stock an “outperform” rating in a research report on Wednesday, November 19th. Fifteen equities research analysts have rated the stock with a Buy rating and eleven have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $110.28.

Medtronic Trading Up 1.9%

Shares of MDT opened at $102.96 on Friday. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.80 and a current ratio of 2.42. Medtronic PLC has a 52-week low of $79.55 and a 52-week high of $106.33. The firm has a market cap of $131.99 billion, a price-to-earnings ratio of 27.75, a PEG ratio of 2.66 and a beta of 0.71. The business’s fifty day moving average is $99.60 and its 200-day moving average is $95.64.

Medtronic (NYSE:MDT) last announced its quarterly earnings data on Tuesday, November 18th. The medical technology company reported $1.36 earnings per share for the quarter, topping the consensus estimate of $1.31 by $0.05. The business had revenue of $8.96 billion during the quarter, compared to the consensus estimate of $8.86 billion. Medtronic had a return on equity of 14.86% and a net margin of 13.71%.Medtronic’s revenue for the quarter was up 6.6% on a year-over-year basis. During the same period in the prior year, the company earned $1.26 EPS. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Equities analysts anticipate that Medtronic PLC will post 5.46 EPS for the current fiscal year.

Medtronic Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, January 16th. Stockholders of record on Friday, December 26th were paid a $0.71 dividend. This represents a $2.84 dividend on an annualized basis and a dividend yield of 2.8%. The ex-dividend date was Friday, December 26th. Medtronic’s dividend payout ratio (DPR) is presently 76.55%.

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).